<SEC-DOCUMENT>0001140361-25-005537.txt : 20250221
<SEC-HEADER>0001140361-25-005537.hdr.sgml : 20250221
<ACCEPTANCE-DATETIME>20250221210526
ACCESSION NUMBER:		0001140361-25-005537
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250219
FILED AS OF DATE:		20250221
DATE AS OF CHANGE:		20250221

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			FINGER ALISON CECILY
		CENTRAL INDEX KEY:			0001731164
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		25653943

	MAIL ADDRESS:	
		STREET 1:		C/O BLUEBIRD BIO, INC.
		STREET 2:		60 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-02-19</periodOfReport>

    <issuer>
        <issuerCik>0001368514</issuerCik>
        <issuerName>ADMA BIOLOGICS, INC.</issuerName>
        <issuerTradingSymbol>ADMA</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001731164</rptOwnerCik>
            <rptOwnerName>FINGER ALISON CECILY</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ADMA BIOLOGICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>465 STATE ROUTE 17</rptOwnerStreet2>
            <rptOwnerCity>RAMSEY</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07446</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-02-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>10889</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>34929</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>16.07</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-02-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>16279</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-02-19</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>16279</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>16279</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These shares represent restricted stock units (&quot;RSUs&quot;) that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.</footnote>
        <footnote id="F2">Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 RSUs granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (iii) 12,020 shares of common stock owned by the Reporting Person.</footnote>
        <footnote id="F3">The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Alison C. Finger, by Adam S. Grossman as Attorney-in-fact</signatureName>
        <signatureDate>2025-02-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ef20044143_ex24.htm
<DESCRIPTION>EXHIBIT 24
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 25.1.1.5279
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: right; font-weight: bold;"> Exhibit 24<br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">LIMITED POWER OF ATTORNEY</div>
    <div style="text-align: center; font-weight: bold;">FOR SECTION 16(a) REPORTING</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Adam S. Grossman, President and Chief Executive
      Officer, and Michael A. Goldstein, Senior Director, General Counsel, of ADMA Biologics, Inc. (the &#8220;Company&#8221;), and each of them, as the undersigned&#8217;s true and lawful attorney-in-fact (the &#8220;Attorney-in Fact&#8221;), with full power of substitution and
      resubstitution, with the power to act alone for the undersigned and in the undersigned&#8217;s name, place and stead, in any and all capacities to:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;prepare, execute and submit to the Securities and Exchange Commission
        (&#8220;SEC&#8221;), any national securities exchange and the Company any and all reports (including any amendment thereto) of the undersigned required or considered advisable under Section 16(a) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), and
        the rules and regulations thereunder, with respect to the equity securities of the Company, including Form 3 (Initial Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes in Beneficial Ownership), and Form 5 (Annual
        Statement of Changes in Beneficial Ownership); and</div>
    <div>&#160;</div>
    <div style="text-align: justify;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;seek or obtain, as the undersigned&#8217;s representative and on the
        undersigned&#8217;s behalf, information regarding transactions in the Company&#8217;s equity securities from any third party, including the Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby
        authorizes any such third party to release any such information to the Attorney-in-Fact.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned acknowledges that:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Limited Power of Attorney authorizes, but does not require, the
        Attorney-in-Fact to act at his discretion on information provided to such Attorney-in-Fact without independent verification of such information;</div>
    <div>&#160;</div>
    <div style="text-align: justify;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any documents prepared and/or executed by the Attorney-in-Fact on behalf
        of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his discretion, deems necessary or desirable;</div>
    <div>&#160;</div>
    <div style="text-align: justify;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;neither the Company nor the Attorney-in-Fact assumes any liability for
        the undersigned&#8217;s responsibility to comply with the requirements of Section 16 of the Exchange Act, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits
        under Section 16(b) of the Exchange Act; and</div>
    <div>&#160;</div>
    <div style="text-align: justify;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;this Limited Power of Attorney does not relieve the undersigned from
        responsibility for compliance with the undersigned&#8217;s obligations under Section 16 of the Exchange Act, including, without, limitation, the reporting requirements under Section 16(a) of the Exchange Act.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or
      convenient to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his substitute or substitutes, shall
      lawfully do or cause to be done by authority of this Limited Power of Attorney.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect
      to the undersigned&#8217;s holdings of and transactions in equity securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">This Limited Power of Attorney shall be governed by and construed in accordance the laws of the State of Delaware without regard to the laws that
      might otherwise govern under applicable principles of conflicts of laws thereof.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of March 28, 2024.</div>
    <div>&#160;</div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="zfb0c1f865b6540f280c9ea9b526f5ab2">

            <tr>
              <td style="width: 35%;"><br>
              </td>
              <td style="width: 15%;">Signature:</td>
              <td style="width: 50.00%;"><u>/s/ Alison C. Finger</u></td>
            </tr>
            <tr>
              <td style="width: 35%;"><br>
              </td>
              <td style="width: 15%;">Print Name: </td>
              <td style="width: 50.00%;">Alison C. Finger</td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
